Sponsor content

Enhanced immuno-viral therapy for solid tumors

Icell Kealex Therapeutics is developing oncolytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. The company is entering phase 1 trials for solid tumors with its lead product and is looking to partner with companies interested in clinical codevelopment of its wide-ranging therapeutic pipeline.

0
0
Upvote 0 Comment
Page of
Go to the profile of Icell Kealex Therapeutics

Icell Kealex Therapeutics

Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships
1 Contributions
7 Followers
23 Following

Please sign in or register for FREE to comment